Bradley Phillips, MD
Ophthalmology · Brooklyn, NYNPI 1104800143
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,670 of the $14,822 with a category attached, or 85.5%. 30 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.5% of the total. Reporting peaked in 2024 at $5,088 and has fallen 65.3% since, to $1,768 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $48.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$4K
- Alcon$3K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Sight Sciences, Inc.$902
- Aerie Pharmaceuticals, Inc.$586
- plus $4K from 24 others
What the payments were for
- Travel & lodging$2,15015%
- Food & beverage$12,67085%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 51 | $3,931 |
| Alcon | 39 | $2,503 |
| AbbVie(2 entities) | 55 | $1,511 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,199 |
| Sight Sciences, Inc. | 13 | $902 |
| Aerie Pharmaceuticals, Inc. | 6 | $586 |
| Glaukos Corporation | 4 | $526 |
| Novartis | 43 | $512 |
| Biotissue Holdings Inc. | 13 | $481 |
| Carl Zeiss Meditec USA, Inc. | 3 | $429 |
| Amgen(2 entities) | 8 | $349 |
| NEW World Medical,inc. | 2 | $262 |
| Oyster Point Pharma, Inc. | 13 | $227 |
| Kala Pharmaceuticals, Inc. | 12 | $205 |
| Sun Pharmaceutical Industries Inc. | 7 | $174 |
| Genentech USA, Inc. | 2 | $153 |
| Dompe US, Inc. | 6 | $151 |
| Catalyst Pharmaceuticals, Inc. | 2 | $127 |
| Rayner Intraocular Lenses Limited | 1 | $105 |
| Mallinckrodt Hospital Products Inc. | 5 | $99 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Ivantis, Inc | 1 | $71 |
| Tarsus Pharmaceuticals, Inc. | 2 | $69 |
| Harrow Eye, LLC | 2 | $49 |
| Astellas Pharma US Inc | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Travere Therapeutics, Inc. | 3 | $18 |
| Argenx US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista Aspire IOL$1,486
- TENEO$1,486
- STELLARIS ELITE$1,486
- Tecnis 1-piece IOL$1,022
- Tecnis Multifocal Family of 1-piece IOLS$1,022
- Tecnis Symfony IOL$1,022
- OMNI(R) SURGICAL SYSTEM (US)$701
- enVista MX60 IOL$690
- Rhopressa$543
- MIEBO$518
- iDose$392
- Rocklatan$361
- XIIDRA$360
- LenSx$325
- Clareon$283
- ARGOS$224
- NGENUITY$167
- Ahmed Glaucoma Valve$164
- Kahook Dual Blade$164
- TEPEZZA$150
How this compares
$14,822 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 658 | $557,151 |
| XiidraLifitegrast | 415 | $309,616 |
| LumiganBimatoprost | 343 | $151,033 |
| Cyclosporine | 229 | $76,389 |
| MieboPerfluorohexyloctane/Pf | 55 | $49,982 |
| CombiganBrimonidine Tartrate/Timolol | 80 | $34,345 |
| Brimonidine Tartrate | 272 | $33,923 |
| RhopressaNetarsudil Mesylate | 64 | $29,472 |
| CequaCyclosporine | 24 | $17,767 |
| Prednisolone Acetate | 317 | $17,479 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $14,614 |
| Travoprost | 87 | $12,796 |
| VyzultaLatanoprostene Bunod | 36 | $11,545 |
| Latanoprost | 1,459 | $10,194 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $8,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,511 | $748,6811,101 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $3,931 | $371,143506 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $586 | $44,08691 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $174 | $17,76724 claims |
| AlconSimbrinza | $2,503 | $8,62536 claims |
| NovartisTravatan Z | $512 | $7,62119 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $19 | $3,34616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Brooklyn
- David RubaltelliBrooklyn$8.9M
- Irene GladsteinBrooklyn$94K
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.